6.2.1.2.3. magnetic resonance imaging selection active surveillance. men eligible based upon systematic biopsy findings alone pre-biopsy mri, re-biopsy within six twelve months months (usually referred ‘confirmatory biopsy’) seems mandatory exclude sampling error. large body literature including two rcts sr, showed adding mri-targeted biopsy systematic sampling confirmatory biopsy improved detection isup grade group ≥ 2 cancers thus, patient selection [121,499-504]. adding mri-targeted biopsy systematic sampling confirmatory biopsy improved upgrade detection increments 0-7.9 per 100 men depending series . meta-analysis 6 studies, rate upgrading isup grade group ≥ 2 cancer increased 20% (95% ci: 16–25%) 27% (95% ci: 22–34%) mri-targeted biopsy added systematic biopsy . active surveillance mri study (asist) randomised men scheduled confirmatory biopsy either 12-core systematic biopsy mri targeted biopsy (when indicated), combined systematic biopsy (up 12 cores total). two years follow-up, use mri confirmatory biopsy resulted fewer failures surveillance (19% vs. 35%, p = 0.017) fewer patients progressing isup grade group ≥ 2 cancer (9.9% vs. 23%, p = 0.048) . however, systematic biopsy retains additional value, argues combined biopsy approach . detective study agreed men eligible combined systematic- mri-targeted biopsy require confirmatory biopsy, recommendation supported results mrias trial . pca diagnosis made mri-targeted biopsy alone order lower risk over-detection insignificant (see 5.4.1 5.4.2.), confirmative systematic biopsy performed definite decision rule widespread cancer growth prostate . studies indicate psma-pet-ct psma-pet-mri may additional value mentioned clinico-pathological variables risk stratification . however, far, studies small follow-up short draw hard conclusions modality recommended outside clinical trials.